MA
DBTX

MYDA Advisors’s Decibel Therapeutics, Inc. Common Stock DBTX Stock Holding History

MYDA Advisors’s Portfolio DBTX Stock Details DBTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-15,000
Closed -$63K – 227
2022
Q2 		$63K Sell
15,000
-5,000
-25% -$11.8K 0.02% 172
2022
Q1 		$61K Buy
+20,000
New +$76.6K 0.02% 177

Other funds holding DBTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Alphabet Inc
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bessemer Group
Bessemer Group Woodbridge, New Jersey $72.7B AUM 39.36% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

MYDA Advisors's DBTX Position: Q3 2022 in Review

MYDA Advisors sold out of Decibel Therapeutics, Inc. Common Stock (DBTX) in Q3 2022, closing a stake of 15,000 shares — an estimated $63K sold.

MYDA Advisors first reported a position in DBTX in Q1 2022 and held it in 2 quarters. The position peaked at $63K in Q2 2022. 40 funds tracked by Wall St. Rank hold DBTX as of Q3 2022.

  • MYDA Advisors reported no remaining Decibel Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • MYDA Advisors sold 15,000 Decibel Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $63K.
  • MYDA Advisors first reported a position in Decibel Therapeutics, Inc. Common Stock in Q1 2022 and held it in 2 quarters.
  • MYDA Advisors's Decibel Therapeutics, Inc. Common Stock position peaked at $63K in Q2 2022.
  • 40 funds tracked by Wall St. Rank held Decibel Therapeutics, Inc. Common Stock as of Q3 2022.

Based on MYDA Advisors's 13F filing for Q3 2022, filed 10 Nov 2022.